Tyrosine Kinase Inhibitor-induced Carotid Stenosis: A Case Report

Overview

Journal Leuk Res Rep

Date 2019 Jun 14

PMID 31194170

Citations 1

Authors

Jeanne Hersant

Martine Gardembas

Georges Leftheriotis

Patrick Vandeputte

Pierre Abraham

Samir Henni

Affiliations

Soon will be listed here.

Abstract

Tyrosine kinase inhibitors are considered as highly effective and relatively safe drugs for the treatment of chronic myeloid leukemia. If several side effects on short and long term are well known and described, their involvement in the development of carotid stenosis remains unclear. Here, we describe a case of carotid stenosis in a patient receiving tyrosine kinase inhibitors and discuss the current literature.

Citing Articles

Isolated pulmonary vasculitis associated with nilotinib use: A case report.

Morris N, Taylor M, Hacobian M, Olevsky O, Kermani T Leuk Res Rep. 2020; 14:100214.

PMID: 32612923 PMC: 7322170. DOI: 10.1016/j.lrr.2020.100214.

References

Gugliotta G, Castagnetti F, Breccia M, Levato L, DAdda M, Stagno F . Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. Haematologica. 2015; 100(9):1146-50. PMC: 4800682. DOI: 10.3324/haematol.2015.129221. View

Moslehi J, Deininger M . Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol. 2015; 33(35):4210-8. PMC: 4658454. DOI: 10.1200/JCO.2015.62.4718. View

Sprynger M, Rigo F, Moonen M, Aboyans V, Edvardsen T, de Alcantara M . Focus on echovascular imaging assessment of arterial disease: complement to the ESC guidelines (PARTIM 1) in collaboration with the Working Group on Aorta and Peripheral Vascular Diseases. Eur Heart J Cardiovasc Imaging. 2018; 19(11):1195-1221. DOI: 10.1093/ehjci/jey103. View

Bondon-Guitton E, Combret S, Perault-Pochat M, Steve-Dumont M, Bagheri H, Huguet F . Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy. Target Oncol. 2016; 11(4):549-52. DOI: 10.1007/s11523-016-0417-x. View

Rix U, Hantschel O, Durnberger G, Remsing Rix L, Planyavsky M, Fernbach N . Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007; 110(12):4055-63. DOI: 10.1182/blood-2007-07-102061. View

Druker B, Lydon N . Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000; 105(1):3-7. PMC: 382593. DOI: 10.1172/JCI9083. View

Aghel N, Lipton J, Atenafu E, Kim D, Delgado D . Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up. Clin Lymphoma Myeloma Leuk. 2017; 17(12):870-878.e1. DOI: 10.1016/j.clml.2017.07.006. View

Alhawiti N, Burbury K, Kwa F, OMalley C, Shuttleworth P, Alzard M . The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. Thromb Res. 2016; 145:54-64. DOI: 10.1016/j.thromres.2016.07.019. View

Grant E, Benson C, Moneta G, Alexandrov A, Baker J, Bluth E . Carotid artery stenosis: gray-scale and Doppler US diagnosis--Society of Radiologists in Ultrasound Consensus Conference. Radiology. 2003; 229(2):340-6. DOI: 10.1148/radiol.2292030516. View

10.

Steegmann J, Baccarani M, Breccia M, Casado L, Garcia-Gutierrez V, Hochhaus A . European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016; 30(8):1648-71. PMC: 4991363. DOI: 10.1038/leu.2016.104. View

11.

Yoshimura T, Matsuyama W, Kamohara H . Discoidin domain receptor 1: a new class of receptor regulating leukocyte-collagen interaction. Immunol Res. 2005; 31(3):219-30. DOI: 10.1385/IR:31:3:219. View